BioCentury | Aug 6, 2015
Product R&D

Impede a fever

...of the antibody on a weekly basis," said Sean Du, COO of infectious disease company Altravax Inc....
...undisclosed infectious agents. Companies and Institutions Mentioned Agency for Science Technology and Research (A*STAR), Singapore Altravax Inc....
...and envelope proteins for four dengue virus serotypes formulated with the Vaxfectin adjuvant Phase I Altravax Inc....
BioCentury | Dec 5, 2013
Distillery Therapeutics

Indication: Infectious disease

...Next steps include evaluating how mAbs targeting envelope protein interact with the critical residue regions. Altravax Inc....
BioCentury | Nov 11, 2013
Company News

Altravax management update

Altravax Inc. , Fargo, N.D. Business: Infectious Hired: Sean Du as COO, formerly executive director at Simcere Pharmaceutical Group 's Institute of Vaccine Research WIR Staff Infectious...
BioCentury | Jan 14, 2013
Company News

Altravax, National Institutes of Health infectious news

...The company plans to move the HBV vaccine into the clinic after it secures funding. Altravax Inc....
BioCentury | Mar 1, 2010
Company News

AltraVax, Maxygen deal

...Newco AltraVax received exclusive, worldwide rights to use Maxygen's MolecularBreeding technology for vaccine identification and development...
...directed evolution, a process of recombining genes homologous to target proteins to create new proteins. AltraVax...
...12-18 months. Maxygen retains certain rights to the underlying IP. Financial terms were not disclosed. AltraVax Inc....
Items per page:
1 - 5 of 5
BioCentury | Aug 6, 2015
Product R&D

Impede a fever

...of the antibody on a weekly basis," said Sean Du, COO of infectious disease company Altravax Inc....
...undisclosed infectious agents. Companies and Institutions Mentioned Agency for Science Technology and Research (A*STAR), Singapore Altravax Inc....
...and envelope proteins for four dengue virus serotypes formulated with the Vaxfectin adjuvant Phase I Altravax Inc....
BioCentury | Dec 5, 2013
Distillery Therapeutics

Indication: Infectious disease

...Next steps include evaluating how mAbs targeting envelope protein interact with the critical residue regions. Altravax Inc....
BioCentury | Nov 11, 2013
Company News

Altravax management update

Altravax Inc. , Fargo, N.D. Business: Infectious Hired: Sean Du as COO, formerly executive director at Simcere Pharmaceutical Group 's Institute of Vaccine Research WIR Staff Infectious...
BioCentury | Jan 14, 2013
Company News

Altravax, National Institutes of Health infectious news

...The company plans to move the HBV vaccine into the clinic after it secures funding. Altravax Inc....
BioCentury | Mar 1, 2010
Company News

AltraVax, Maxygen deal

...Newco AltraVax received exclusive, worldwide rights to use Maxygen's MolecularBreeding technology for vaccine identification and development...
...directed evolution, a process of recombining genes homologous to target proteins to create new proteins. AltraVax...
...12-18 months. Maxygen retains certain rights to the underlying IP. Financial terms were not disclosed. AltraVax Inc....
Items per page:
1 - 5 of 5